Oslo, Norway, 13 June 2018
Nordic Nanovector ASA (OSE: NANO) has received approval from the Regional
Committees for Medical and Health Research Ethics (REK) in Norway with regard to
the Clinical Trial Application (CTA) for the Archer-1 Phase 1b trial with
Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab in
second-line follicular lymphoma patients (2L FL).
Nordic Nanovector has now received all necessary approvals to begin Archer-1 in
Norway and will commence start-up activities immediately. Archer-1 is a Phase 1b
clinical trial designed to investigate the safety, tolerability, pharmacokinetic
and preliminary efficacy of the Betalutin®/rituximab combination in approx. 20
2L FL patients, and the study will initially be conducted in Norway. Further
countries are expected to be added later. The first patient is expected to be
dosed in the second half of 2018.
For further information, please contact:
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
International Media Enquiries
Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting antibody-radionuclide-conjugate designed to advance the treatment of
non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet
medical need, representing a growing market forecast to be worth nearly USD 20
billion by 2024. Nordic Nanovector intends to retain marketing rights and to
actively participate in the commercialisation of Betalutin® in core markets.
Further information about the Company can be found at www.nordicnanovector.